Boundless Bio Advances KOMODO-1 Trial with $93M Cash Runway
Event summary
- Enrollment ongoing in KOMODO-1 first-in-human trial for BBI-940 in breast cancer patients.
- $92.8M cash position provides runway through mid-2028.
- AACR 2026 data shows BBI-940's anti-tumor activity across multiple ecDNA+ cancer models.
- Q1 2026 R&D expenses down 19.8% YoY to $9.7M.
- Net loss of $13.6M in Q1 2026, a 13.9% decrease from Q1 2025.
The big picture
Boundless Bio's progress in the KOMODO-1 trial positions it at the forefront of a new wave of oncology treatments targeting extrachromosomal DNA (ecDNA). The company's focus on ecDNA-directed therapeutics addresses a significant unmet need in patients with oncogene amplified tumors, a subset representing 14-17% of cancer patients. With a strong cash position and promising preclinical data, Boundless Bio is well-positioned to capitalize on the growing interest in precision oncology therapies.
What we're watching
- Clinical Progress
- How the pace of KOMODO-1 trial enrollment and initial data readouts will impact Boundless Bio's valuation.
- Cash Management
- Whether the current $93M cash position will be sufficient to reach key clinical milestones without additional funding.
- Competitive Positioning
- The extent to which BBI-940's unique mechanism of targeting ecDNA will differentiate it in the crowded oncology space.
Related topics